MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers17071140

Медицинская библиотека · Cancers · 2025

Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases.

Suh Hyung C, Rowley Scott D, Kaur Sukhdeep, Lukasik Brittany, McKiernan Phyllis, Boonstra Michele, Baker Melissa, DiLorenzo Mary, Skarbnik Alan, Voss Jason, Hampson Alexandra, DeAgresta Bianca, Boylan Brighid, Nyirenda Themba, Vesole David H, Donato Michele L

СтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

Allogeneic hematopoietic stem cell transplantation (alloSCT) is a curative treatment for myeloid diseases, yet relapse remains the major cause of post-transplant mortality. To reduce the risk of recurrence, we evaluated the addition of 400 cGy total body irradiation (TBI) to conditioning with fludarabine-busulfan (Flu/Bu4).

Methods

In this prospective study, 46 patients with myeloid diseases were randomized to Flu/Bu4 or Flu/Bu4/TBI conditioning group. The Flu/Bu4 conditioning regimen consisted of fludarabine 40 mg/m2 on days -6 to -3 followed by busulfan 130 mg/m2 on days -6 to -3. Flu/Bu4/TBI conditioning regimen added 400 cGy TBI on day -1 to the FluBu4 regimen.

Results

Among 34 acute myeloid leukemia (AML) patients, relapse was numerically lower in those who received Flu/Bu4/TBI (25%) versus Flu/Bu4 (44.4%) at three years (HR = 0.58, 95% CI 0.19 to 1.81, p = 0.35). Flu/Bu4/TBI appeared to increase the risk of non-relapse mortality (NRM) vs. Flu/Bu4 in AML patients at three years (25.0% versus 11.1%; HR = 2.11, 95% CI 0.51 to 8.83, p = 0.65). Overall survival (OS) was similar in AML patients undergoing conditioning with Flu/Bu4 (72.2%) versus Flu/Bu4/TBI (62.5%) at one year (p = 0.4).

Conclusions

In conclusion, the addition of 400 cGy TBI to Flu/Bu4 reduced the risk of relapse but did not improve OS as a consequence of higher regimen-related mortality. Clinicaltrials.gov identifier: NCT01366612.

Для цитирования: Suh Hyung C, Rowley Scott D, Kaur Sukhdeep, Lukasik Brittany, McKiernan Phyllis, Boonstra Michele, Baker Melissa, DiLorenzo Mary, Skarbnik Alan, Voss Jason, Hampson Alexandra, DeAgresta Bianca, Boylan Brighid, Nyirenda Themba, Vesole David H, Donato Michele L. Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases.. Cancers. 2025. DOI: 10.3390/cancers17071140.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.